Skip to main content
OpenTrials
Completed

NCT Number: NCT03569371

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hidradenitis Suppurativa Bacterial Infections Bacterial Infections and Mycoses Hidradenitis Infections Skin Diseases Skin Diseases, Bacterial Skin Diseases, Infectious Skin and Connective Tissue Diseases Suppuration Sweat Gland Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Investigative Site, Los Angeles, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of HS (confirmed by a dermatologist) with a disease duration of at least 6 months before screening.
  • Stable course of HS for at least 90 days before screening, as determined by the investigator.
  • HS lesions present in at least 2 distinct anatomic areas, 1 of which must be Hurley Stage II or III at screening and baseline.
  • Total AN count of at least 3 at screening and baseline.
  • Male participants must agree to use contraception per protocol-defined criteria.

Exclusion criteria

  • Women of childbearing potential or who are currently pregnant or lactating.
  • Presence of > 20 draining fistulas at screening and baseline.
  • Participants with concurrent conditions or history of other diseases as follows:
  • Any clinically significant medical condition other than HS, as determined by the investigator, that is not adequately controlled with appropriate treatment.
  • Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with the course, severity, or assessments of HS.
  • Active systemic viral infection or any active viral infection that, based on the investigator's clinical assessment, make the participant an unsuitable candidate for the study.
  • Current herpes zoster infection, a history of recurrent herpes zoster, a history of disseminated herpes simplex, or a history of herpes zoster.
  • History of malignancy, including lymphoma and leukemia within 5 years before baseline, other than a successfully treated nonmetastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or localized carcinoma in situ of the cervix.
  • Albinism.
  • Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF), defined as ≥ 450 msec.
  • Positive test result for tuberculosis (TB) from the QuantiFERON-TB Gold test, or equivalent, at screening (or, if 2 indeterminate tests or not available, then as evaluated by a purified protein derivative test with a result of < 5 mm of induration within 3 months of screening) or a history of active TB.
  • Positive serology test results for HIV, HBsAg, hepatitis B virus (HBV) core antibody, or HCV (HCV antibody with positive HCV-RNA) at screening.
  • Decreased blood cell counts at screening as per protocol-defined parameters.
  • Severely impaired liver function (Child-Pugh Class C) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥ 1.5 × upper limit of normal (ULN).
  • Impaired renal function with serum creatinine > 1.5 mg/dL.
  • Use of prohibited medications per protocol-defined criteria.
  • Known or suspected allergy to INCB054707 or any component of the study drug.
  • Known history of clinically significant drug or alcohol abuse in the last year prior to baseline.
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Treatment and study plan

INCB054707

Drug

INCB054707 administered once daily orally with water without regard to food for 8 weeks.

Other names: Povorcitinib

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 12 weeks.

    A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.

Secondary outcomes

  1. Apparent Oral Clearance of INCB054707(CL/F)

    Time frame: Postdose Day1, week 2 and 6

    To evaluate the systemic exposure to INCB054707.

  2. Apparent Oral Volume of Distribution of INCB054707(Vc/F)

    Time frame: Postdose Day1, week 2 and 6.

    To evaluate the systemic exposure to INCB054707.

  3. Absorption Constant of INCB054707 (Ka)

    Time frame: Postdose Day1, week 2 and 6.

    Other population pharmacokinetic (PK) model parameter that the PK model may include to evaluate the systemic exposure to INCB054707.

  4. Apparent Inter-compartmental Clearance(Q/F)

    Time frame: Postdose Day1, week 2 and 6.

    Other population PK model parameter that the PK model may include to evaluate the systemic exposure to INCB054707.

  5. Proportion of Participants With a Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit

    Time frame: Weeks 1,2,4,6,8 and FollowUp

    An HiSCR is defined as at least 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline at each visit.

  6. Proportion of Participants Achieving an AN Count of 0 to 2 at Each Visit

    Time frame: Weeks 1,2,4,6,8 and FollowUp

    The number and proportion of participants who achieved an Abscess and Inflammatory nodule count of 0 to 2 progressively.

  7. Mean Change From Baseline in the HS Pain Numeric Rating Scale (NRS) Scores at Each Visit

    Time frame: Weeks 1,2,4,6,8 and FollowUp

    The HS Pain NRS will be completed in a daily diary by participants from screening through EOS. An 11-point scale will be used to assess the worst skin pain due to HS based on a recall period of the last 24 hours. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine)

  8. Mean Change From Baseline in the Modified Sartorius Scale Score

    Time frame: Week 8.

    The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS.

  9. Mean Change From Baseline in the Number of Draining Fistulas Count at Each Visit

    Time frame: Up to approximately 12 weeks.

    Draining fistulas are fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.

  10. Proportion of Participants at Each Category of Hurley Stage

    Time frame: Baseline and Week 8.

    The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows:

    Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring).

    Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring).

    Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.

  11. Proportion of Participants With Change From Baseline to Week 8 in Hurley Stage

    Time frame: Week 8.

    The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows:

    Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring).

    Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring).

    Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.

  12. Proportions of Participants in Each HS Patient Global Impression of Change (PGIC) Category

    Time frame: Up to approximately 12 weeks.

    The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse.

  13. Proportion of Participants Requiring Rescue Lesional Treatment

    Time frame: Up to approximately 12 weeks.

    Rescue lesional treatment is defined as immediate intervention in the event of an acutely painful lesion.

  14. Number of Interventions With Rescue Lesional Treatment

    Time frame: Up to approximately 12 weeks.

    Rescue lesional treatment is defined as immediate intervention in the event of an acutely painful lesion.

  15. Proportion of Participants at Each Scoring Category of the Dermatology Life Quality Index (DLQI) at Each Visit

    Time frame: Up to approximately 12 weeks.

    The DLQI is a questionnaire used to assess the symptoms and the impact of skin problems on quality of life. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The meaning of DLQI scores can be categorized as follows: 0-1 = No effect at all on patient's life 2-5 = Small effect on patient's life 6-10 = Moderate effect on patient's life 11-20 = Very large effect on patient's life 21-30 = Extremely large effect on patient's life

Sponsors and collaborators

Lead sponsor

Incyte Corporation

Industry

Registry information

Official study title

A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 26, 2018
Registry last updated
Sep 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.